ICMR Transfers Three Indigenous Biomedical Technologies for Cancer and Infectious Disease Treatment
The SHetA2 anti-HPV therapeutic candidate has been licensed to Emcure Pharmaceuticals Limited for further development. The technology is intended for the treatment of Cervical Intraepithelial Neoplasia, a precancerous condition associated with persistent human papillomavirus infection.